modelR06AX02
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Cyproheptadine | |
| ATC code: | R06AX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 4 | mg |
| volume of distribution: | 20 | L |
| clearance: | 1600 | ml/h/kg |
| other parameters in model implementation | ||
Cyproheptadine is a first-generation antihistamine with anticholinergic, antiserotonergic, and sedative properties. It is primarily used for the symptomatic relief of allergic conditions such as rhinitis, urticaria, and conjunctivitis. It has also been used for appetite stimulation, migraine prophylaxis, and treatment of serotonin syndrome. Cyproheptadine is an approved drug and is available in many countries.
Pharmacokinetics
Pharmacokinetic parameters for healthy adult volunteers after a single oral dose.
References
Paton, DM, & Webster, DR (1985). Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clinical pharmacokinetics 10(6) 477–497. DOI:10.2165/00003088-198510060-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2866055
Peña, J, et al., & Merlos, M (2008). Antihistaminic effects of rupatadine and PKPD modelling. European journal of drug metabolism and pharmacokinetics 33(2) 107–116. DOI:10.1007/BF03191027 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18777946
Xiong, Y, et al., & Liu, M (2016). CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. European journal of drug metabolism and pharmacokinetics 41(2) 117–124. DOI:10.1007/s13318-014-0236-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25427746
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)